-
公开(公告)号：US20210275453A1
公开(公告)日：2021-09-09
申请号：US17184928
申请日：2021-02-25
Applicant: FUJIFILM Corporation
Inventor： Tsukasa KITAHASHI , Shinji MIMA , Takeshi MATSUMOTO , Takahiro SEKIGUCHI , Mikinaga MORI
IPC: A61K9/127 , A61K47/24 , A61K47/28 , A61K31/337 , A61K31/7068 , A61P35/00
Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.
-
公开(公告)号：US20170042813A1
公开(公告)日：2017-02-16
申请号：US15336158
申请日：2016-10-27
Applicant: FUJIFILM Corporation
Inventor： Makoto ONO , Kohei ONO , Takeshi MATSUMOTO , Mikinaga MORI
IPC: A61K9/127 , A61K31/7068
CPC classification number: A61K9/127 , A61K9/1278 , A61K31/7068 , A61K47/24 , A61K47/28 , B82Y5/00
Abstract: Provided are a liposome composition in which an osmotic pressure of an inner water phase is 2-fold to 8-fold relative to the osmotic pressure of an outer water phase, and which encapsulates a water-soluble drug in a dissolved state, and also exhibits excellent preservation stability; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes obtained from lipids dissolved and emulsified in an organic solvent, each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a water-soluble drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase; and a method for producing the same.
Abstract translation: 提供一种脂质体组合物，其中内水相的渗透压相对于外部水相的渗透压为2倍至8倍，并且将水溶性药物包封在溶解状态，并且还显示出 保存稳定性好; 及其制造方法。 根据本发明，可以提供一种脂质体组合物，其包括由在有机溶剂中溶解和乳化的脂质获得的脂质体，每个脂质体具有构成外部水相的内部水相和水溶液， 分散脂质体，其中每个脂质体包封溶解状态的水溶性药物，内部水相的渗透压相对于外部水相的渗透压为2倍至8倍; 及其制造方法。
-
公开(公告)号：US20170042811A1
公开(公告)日：2017-02-16
申请号：US15336057
申请日：2016-10-27
Applicant: FUJIFILM Corporation
Inventor： Makoto ONO , Kohei ONO , Takeshi MATSUMOTO , Mikinaga MORI
IPC: A61K9/127 , A61K31/7068
CPC classification number: A61K9/127 , A61K9/1278 , A61K31/7068 , A61K47/24 , A61K47/28 , B01J13/02 , B01J13/20 , Y10S977/773 , Y10S977/906 , Y10S977/907
Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.
Abstract translation: 本发明提供一种脂质体组合物，其具有实际上所需的长期保存稳定性，并且由于能够通过使内部水分适当地控制药物的释放性，其具有几十小时数量级的药物的释放速率 相超渗透 及其制造方法。 根据本发明，可以提供一种脂质体组合物，其包括脂质体，其各自具有构成外部水相的内部水相和水溶液，并且其中分散有脂质体的胆固醇的含量为 相对于脂质体组合物中的脂质成分的总量为10〜35摩尔％，并且每个脂质体将药物包封在溶解状态，内部水相的渗透压为2倍至8倍， 相对于外部水相的渗透压折叠。
-
公开(公告)号：US20210100745A1
公开(公告)日：2021-04-08
申请号：US17121870
申请日：2020-12-15
Applicant: FUJIFILM Corporation
Inventor： Makoto ONO , Kohei ONO , Takeshi MATSUMOTO , Mikinaga MORI
Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.
-
公开(公告)号：US20170202774A1
公开(公告)日：2017-07-20
申请号：US15474644
申请日：2017-03-30
Applicant: FUJIFILM Corporation
Inventor： Makoto ONO , Kohei ONO , Takeshi MATSUMOTO , Mikinaga MORI
IPC: A61K9/127 , A61K31/7068
CPC classification number: A61K9/127 , A61K9/1278 , A61K31/7068 , A61K47/24 , A61K47/28 , B82Y5/00
Abstract: Provided are a liposome composition in which an osmotic pressure of an inner water phase is 2-fold to 8-fold relative to the osmotic pressure of an outer water phase, and which encapsulates a water-soluble drug in a dissolved state, and also exhibits excellent preservation stability; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes obtained from lipids dissolved and emulsified in an organic solvent, each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which each of the liposomes encapsulates a water-soluble drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase; and a method for producing the same.
-
Patent Agency Ranking
公开(公告)号：US20240099975A1
公开(公告)日：2024-03-28
申请号：US18517448
申请日：2023-11-22
Applicant: FUJIFILM Corporation
Inventor： Susumu SHIMOYAMA , Keiko SUZUKI , Mikinaga MORI , Takeshi MATSUMOTO , Shinji NAKAYAMA , Yasushi MOROHASHI , Toshifumi KIMURA
CPC classification number: A61K9/1271 , A61K9/0019 , A61K31/4745 , A61K33/04 , A61K47/10 , A61K47/28 , A61K47/544 , A61P35/00
Abstract: An object of the present invention is to provide an anti-tumor agent that exhibits a remarkably excellent anti-tumor effect. According to the present invention, there is provided an anti-tumor agent for curing cancer, the anti-tumor agent having a liposome which has an inner water phase and having an aqueous solution which is an outer water phase and disperses the liposome, in which the liposome encompasses topotecan or a salt thereof, a lipid constituting the liposome contains a lipid modified with polyethylene glycol, dihydrosphingomyelin, and cholesterol, the inner water phase contains an ammonium salt, and the topotecan or the salt thereof encompassed in the liposome is administered at a dose rate of 0.1 mg/m2 body surface area to 10 mg/m2 body surface area, in terms of topotecan per administration.
-
公开(公告)号：US20210106528A1
公开(公告)日：2021-04-15
申请号：US17125291
申请日：2020-12-17
Applicant: FUJIFILM Corporation
Inventor： Takashi KOMORI , Tadaaki IOROI , Takeshi MATSUMOTO , Yasuyuki IZUMI
IPC: A61K9/127 , A61K31/7068 , A61P35/00
Abstract: An object of the present invention is to provide a combined pharmaceutical formulation obtained by combining a liposome composition and an immune checkpoint inhibitor, in which gemcitabine is encapsulated in a dissolved state in liposomes in the liposome composition. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes liposomes each having an inner water phase, and an aqueous solution constituting an outer water phase and having the liposomes dispersed therein, gemcitabine is encapsulated in a dissolved state in the liposomes, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.
-
公开(公告)号：US20190336447A1
公开(公告)日：2019-11-07
申请号：US16511380
申请日：2019-07-15
Applicant: FUJIFILM Corporation
Inventor： MAKOTO ONO , Kohei ONO , Takeshi MATSUMOTO , Mikinaga MORI
Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.
-
9.发明公开公开(公告)号：US20230285295A1
公开(公告)日：2023-09-14
申请号：US18199903
申请日：2023-05-19
Applicant: FUJIFILM Corporation
Inventor： Takashi KOMORI , Tadaaki IOROI , Takeshi MATSUMOTO , Yasuyuki IZUMI
IPC: A61K9/127 , A61P35/00 , A61K31/7068
CPC classification number: A61K9/127 , A61P35/00 , A61K31/7068 , A61K45/06
Abstract: An object of the present invention is to provide a combined pharmaceutical formulation obtained by combining a liposome composition and an immune checkpoint inhibitor, in which gemcitabine is encapsulated in a dissolved state in liposomes in the liposome composition. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes liposomes each having an inner water phase, and an aqueous solution constituting an outer water phase and having the liposomes dispersed therein, gemcitabine is encapsulated in a dissolved state in the liposomes, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.
-
公开(公告)号：US20180243214A1
公开(公告)日：2018-08-30
申请号：US15967970
申请日：2018-05-01
Applicant: FUJIFILM Corporation
Inventor： Tsukasa KITAHASHI , Shinji MIMA , Takeshi MATSUMOTO , Takahiro SEKIGUCHI , Mikinaga MORI
IPC: A61K9/127 , A61K31/7068 , A61K31/337 , A61K47/28 , A61K47/24 , A61P35/00
CPC classification number: A61K9/127 , A61K31/337 , A61K31/7068 , A61K47/24 , A61K47/28 , A61P35/00 , A61K2300/00
Abstract: An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.039 seconds)
